Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Dysplastic Nevi: Classification, Challenges, and Management
Description
The discussion revolves around dysplastic nevi, focusing on their classification, challenges, and management. Dysplastic nevi are complex to characterize due to their uncertain malignant potential and variability in histopathological interpretation among pathologists. Studies have highlighted a lack of agreement in grading dysplastic nevi, emphasizing the difficulty in diagnosis, particularly for moderate dysplastic nevi, where interobserver reliability is notably low. The management of dysplastic nevi remains controversial, with significant variability in practice depending on the clinician's experience and local guidelines. Recent data suggest that mild to moderate dysplastic nevi with clinically positive margins can be monitored without immediate re-excision, while severe dysplastic nevi often require re-excision due to their potential malignancy. Advances in adjunct diagnostic tools, such as immunohistochemistry, can aid in distinguishing between benign and malignant lesions but must be used judiciously alongside traditional histopathological methods. Overall, close observation and regular skin surveillance for patients with dysplastic nevi, especially those with multiple lesions, are recommended. The conversation emphasizes the importance of communication and shared decision-making between the clinician and the patient in managing dysplastic nevi.
View moreConclusions
- The malignant potential of dysplastic nevi remains uncertain, complicating diagnosis and management.
- Histological classification of dysplastic nevi is challenging and inconsistent among pathologists.
- Management of dysplastic nevi varies widely due to a lack of clear guidelines and limited outcome data.
- Most melanomas may arise de novo, rather than from dysplastic nevi, suggesting a need for reevaluation of traditional concepts of dysplasia.
- Moderately dysplastic nevus with positive margins can be monitored safely without immediate re-excision in most cases.
- Close observation with routine skin surveillance is recommended for mild to moderate dysplastic nevi, regardless of margin status.
- Re-excision should be considered for moderate to severe dysplastic nevi, particularly those with atypical features or positive margins.
- A significant proportion of patients with multiple dysplastic nevi (≥2) are at increased risk for subsequent melanomas at separate sites.
- Clinical behavior and pre-biopsy suspicion are critical in deciding biopsy and excision strategies for dysplastic nevi.
- Piepkorn MW, Barnhill RL, Elder DE, Knezevich SR, Carney PA, Reisch LM, Elmore JG. The MPATH-Dx reporting schema for melanocytic proliferations and melanoma. J Am Acad Dermatol. 2014 Jan;70(1):131-41.
- Adamson AS, Nelson KC. Observation of Moderately Dysplastic Nevi With Positive Margins: Are We There Yet ?. JAMA dermatology. 2018 Dec 1;154(12):1387-8.
- Elmore JG, Barnhill RL, Elder DE, Longton GM, Pepe MS, Reisch LM, Carney PA, Titus LJ, Nelson HD, Onega T, Tosteson AN. BMJ. 2017 Jun 28;357:j2813.
- Kim CC, Berry EG, Marchetti MA, et al. Risk of subsequent cutaneous melanoma in moderately dysplastic nevi excisionally biopsied but with positive histologic margins. JAMA dermatology 2016;152:1327-34.
- Hocker TL, Alikhan A, Comfere NI, Peters MS. Favorable long-term outcomes in patients with histologically dysplastic nevi that approach a specimen border. J Am Acad Dermatol. 2013 Apr;68(4):545-551. doi: 10.1016/j.jaad.2012.09.031. Epub 2012 Nov 3. PMID: 23127472.
- Nobre AB, Piñeiro-Maceira J, Luiz RR. Analysis of interobserver reproducibility in grading histological patterns of dysplastic nevi. An Bras Dermatol. 2013 Jan-Feb;88(1):23-31. doi: 10.1590/s0365-05962013000100002. PMID: 23539000; PMCID: PMC3699937.
- Lezcano C, Jungbluth A, Busam KJ. PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions. Surg Pathol Clin. 2021.